Stoke Therapeutics (NASDAQ:STOK) Trading Down 5.6% - What's Next?

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) dropped 5.6% during trading on Tuesday . The company traded as low as $10.00 and last traded at $9.98. Approximately 167,376 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 851,992 shares. The stock had previously closed at $10.57.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Leerink Partners started coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They issued an "outperform" rating and a $18.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Leerink Partnrs raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. Chardan Capital began coverage on Stoke Therapeutics in a report on Friday, December 20th. They set a "buy" rating and a $24.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $21.29.

Stoke Therapeutics Trading Down 7.1 %

The stock has a market cap of $520.17 million, a P/E ratio of -4.68 and a beta of 0.95. The business has a 50-day simple moving average of $11.13 and a 200 day simple moving average of $12.76.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million for the quarter, compared to analysts' expectations of $3.46 million. As a group, equities analysts expect that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,666 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the completion of the sale, the general counsel now directly owns 21,476 shares in the company, valued at approximately $292,288.36. The trade was a 38.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the sale, the insider now directly owns 51,277 shares of the company's stock, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock worth $809,421 over the last quarter. Company insiders own 11.30% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. increased its stake in Stoke Therapeutics by 99.4% during the 2nd quarter. American Century Companies Inc. now owns 59,149 shares of the company's stock valued at $799,000 after purchasing an additional 29,489 shares in the last quarter. Profund Advisors LLC bought a new stake in shares of Stoke Therapeutics during the second quarter worth about $201,000. Millennium Management LLC increased its position in shares of Stoke Therapeutics by 528.6% during the second quarter. Millennium Management LLC now owns 289,067 shares of the company's stock worth $3,905,000 after acquiring an additional 243,083 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock worth $189,000 after acquiring an additional 1,994 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its position in Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock valued at $18,741,000 after acquiring an additional 1,123,500 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.